ALS Association Objects to Use of ‘Failed’ Cost-effectiveness Measures
The ALS Association has formally objected to the use of two controversial measures of cost-effectiveness in the upcoming evaluations of AMX0035 and oral edaravone, which are being reviewed as treatments for amyotrophic lateral sclerosis (ALS) in the U.S. These cost-effectiveness measures fail to value the lives of ALS…